Prognostic and Predictive Value of Tumor-Infiltrating Immune Cells in Urothelial Cancer of the Bladder

Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis.

(2020) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

CD163+ macrophages predict a poor prognosis in patients with primary T1 high-grade urothelial carcinoma of the bladder

(2019) Guoliang Yang et al.   WORLD JOURNAL OF UROLOGY

Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up

(2019) Y Fradet et al.   ANNALS OF ONCOLOGY

Cisplatin Augments Antitumor T-Cell Responses Leading to a Potent Therapeutic Effect in Combination With PD-L1 Blockade

(2019) DAIKO WAKITA et al.   ANTICANCER RESEARCH

Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): Updated follow-up from KEYNOTE-057.

(2019) Ronald De Wit et al.   JOURNAL OF CLINICAL ONCOLOGY

High CD3D/CD4 ratio predicts better survival in muscle-invasive bladder cancer

(2019) Ming-Jun Shi et al.   Cancer Management and Research

Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology

(2019) Gregor Sturm et al.   BIOINFORMATICS

CD83: Activation Marker for Antigen Presenting Cells and Its Therapeutic Potential

(2019) Ziduo Li et al.   Frontiers in Immunology

Prognostic and Clinicopathological Significance of PD-L1 in Patients With Bladder Cancer: A Meta-Analysis

(2019) Lei Zhu et al.   Frontiers in Pharmacology

Correction to: Prognostic Role of the Immunoscore for Patients with Urothelial Carcinoma of the Bladder Who Underwent Radical Cystectomy

(2019) Xiang-Dong Li et al.   ANNALS OF SURGICAL ONCOLOGY

Tumor-associated macrophages expressing galectin-9 identify immunoevasive subtype muscle-invasive bladder cancer with poor prognosis but favorable adjuvant chemotherapeutic response

(2019) Yangyang Qi et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial

(2019) Thomas Powles et al.   NATURE MEDICINE

Identification of Candidates for Salvage Therapy

(2019) Russell E.N. Becker et al.   UROLOGIC CLINICS OF NORTH AMERICA

CD169-positive sinus macrophages in the lymph nodes determine bladder cancer prognosis

(2018) Touko Asano et al.   CANCER SCIENCE

Identification and Validation of Stromal Immunotype Predict Survival and Benefit from Adjuvant Chemotherapy in Patients with Muscle-Invasive Bladder Cancer

(2018) Hangcheng Fu et al.   CLINICAL CANCER RESEARCH

Prognostic Value of Testing PD-L1 Expression After Radical Cystectomy in High-risk Patients

(2018) Renate Pichler et al.   Clinical Genitourinary Cancer

Cisplatin inhibits the progression of bladder cancer by selectively depleting G-MDSCs: A novel chemoimmunomodulating strategy

(2018) Ke Wu et al.   CLINICAL IMMUNOLOGY

Neoadjuvant Chemotherapy Reinforces Antitumour T cell Response in Urothelial Urinary Bladder Cancer

(2018) David Krantz et al.   EUROPEAN UROLOGY

Immune-desert, immune-excluded and inflamed phenotypes predict survival and adjuvant chemotherapy response in patients with MIBC

(2018) Y. Zhu et al.   EUROPEAN UROLOGY SUPPLEMENTS

International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study

(2018) Franck Pagès et al.   LANCET

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial

(2018) Thomas Powles et al.   LANCET

The prognostic values of tumor-infiltrating neutrophils, lymphocytes and neutrophil/lymphocyte rates in bladder urothelial cancer

(2018) Kangkang Liu et al.   PATHOLOGY RESEARCH AND PRACTICE

Myeloid-derived suppressors cells (MDSC) correlate with clinicopathologic factors and pathologic complete response (pCR) in patients with urothelial carcinoma (UC) undergoing cystectomy

(2018) Moshe C. Ornstein et al.   UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS

High expression of B7-H3 and CD163 in cancer tissues indicates malignant clinicopathological status and poor prognosis of patients with urothelial cell carcinoma of the bladder

(2018) Zhili Xu et al.   Oncology Letters

Abstract CT178: Nivolumab monotherapy in patients with advanced platinum-resistant urothelial carcinoma: Efficacy and safety update and association between biomarkers and overall survival in CheckMate 275

(2018) Padmanee Sharma et al.   CANCER RESEARCH

A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).

(2018) Thomas Powles et al.   JOURNAL OF CLINICAL ONCOLOGY

TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells

(2018) Sanjeev Mariathasan et al.   NATURE

Presence of lymphocytic infiltrate cytotoxic T lymphocyte CD3+, CD8+, and immunoscore as prognostic marker in patients after radical cystectomy

(2018) Alice Yu et al.   PLoS One

Tumor stroma-infiltrating mast cells predict prognosis and adjuvant chemotherapeutic benefits in patients with muscle invasive bladder cancer

(2018) Zheng Liu et al.   OncoImmunology

Programmed death ligand‐1 is associated with tumor infiltrating lymphocytes and poorer survival in urothelial cell carcinoma of the bladder

(2018) Bo Wang et al.   CANCER SCIENCE

PD-L1 Antibody Comparison in Urothelial Carcinoma

(2018) Maud Rijnders et al.   EUROPEAN UROLOGY

Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study

(2018) Andrea Necchi et al.   JOURNAL OF CLINICAL ONCOLOGY

Intratumoral CD56bright natural killer cells are associated with improved survival in bladder cancer

(2018) Neelam Mukherjee et al.   Oncotarget

Evaluation of PD-L1 biomarker for immune checkpoint inhibitor (PD-1/PD-L1 inhibitors) treatments for urothelial carcinoma patients: A meta-analysis

(2018) Xin Rui et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

ILC2-modulated T cell–to-MDSC balance is associated with bladder cancer recurrence

(2017) Mathieu F. Chevalier et al.   JOURNAL OF CLINICAL INVESTIGATION

The immune contexture in cancer prognosis and treatment

(2017) Wolf H. Fridman et al.   Nature Reviews Clinical Oncology

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Accumulation of myeloid-derived suppressor cells (MDSCs) induced by low levels of IL-6 correlates with poor prognosis in bladder cancer

(2017) Guoliang Yang et al.   Oncotarget

Eosinophils: The unsung heroes in cancer?

(2017) Gilda Varricchi et al.   OncoImmunology

Tumor-infiltrating neutrophils predict benefit from adjuvant chemotherapy in patients with muscle invasive bladder cancer

(2017) Lin Zhou et al.   OncoImmunology

Upregulation of programmed cell death ligand 1 promotes resistance response in non-small-cell lung cancer patients treated with neo-adjuvant chemotherapy

(2016) Panpan Zhang et al.   CANCER SCIENCE

Human CD56brightNK Cells: An Update

(2016) Tatiana Michel et al.   JOURNAL OF IMMUNOLOGY

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Galectin-9 modulates immunity by promoting Th2/M2 differentiation and impacts survival in patients with metastatic melanoma

(2016) Elizabeth Ann L. Enninga et al.   MELANOMA RESEARCH

CXCL2/MIF-CXCR2 signaling promotes the recruitment of myeloid-derived suppressor cells and is correlated with prognosis in bladder cancer

(2016) H Zhang et al.   ONCOGENE

Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: A Systematic Review and Two-Step Meta-Analysis

(2016) Ming Yin et al.   ONCOLOGIST

Predominance of M2-polarized macrophages in bladder cancer affects angiogenesis, tumor grade and invasiveness

(2016) HISASHI TAKEUCHI et al.   Oncology Letters

The ratio of CD8 to Treg tumor-infiltrating lymphocytes is associated with response to cisplatin-based neoadjuvant chemotherapy in patients with muscle invasive urothelial carcinoma of the bladder

(2016) Alexander S. Baras et al.   OncoImmunology

Association of PD-L1 expression on tumor-infiltrating mononuclear cells and overall survival in patients with urothelial carcinoma

(2015) J. Bellmunt et al.   ANNALS OF ONCOLOGY

Chemotherapy Induces Programmed Cell Death-Ligand 1 Overexpression via the Nuclear Factor- B to Foster an Immunosuppressive Tumor Microenvironment in Ovarian Cancer

(2015) J. Peng et al.   CANCER RESEARCH

Suppressive effects of gemcitabine plus cisplatin chemotherapy on regulatory T cells in nonsmall-cell lung cancer

(2015) Cheng Chen et al.   JOURNAL OF INTERNATIONAL MEDICAL RESEARCH

T-cell immunoglobulin mucin-3 expression in bladder urothelial carcinoma: Clinicopathologic correlations and association with survival

(2015) Meng Yang et al.   JOURNAL OF SURGICAL ONCOLOGY

CD103+ Tumor Infiltrating Lymphocytes Predict a Favorable Prognosis in Urothelial Cell Carcinoma of the Bladder

(2015) Bo Wang et al.   JOURNAL OF UROLOGY

Tumor-Associated Macrophages Provide Significant Prognostic Information in Urothelial Bladder Cancer

(2015) Minna M. Boström et al.   PLoS One

Assessment of Tumoral PD-L1 Expression and Intratumoral CD8+ T Cells in Urothelial Carcinoma

(2015) Sheila F. Faraj et al.   UROLOGY

Correlation of tumor-infiltrating lymphocytes with bladder cancer recurrence in patients with solitary low-grade urothelial carcinoma

(2015) Kristian Krpina et al.   VIRCHOWS ARCHIV

The prognostic effect of tumour-infiltrating lymphocytic subpopulations in bladder cancer

(2015) T. Horn et al.   WORLD JOURNAL OF UROLOGY

High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder

(2015) Bo Wang et al.   Oncotarget

Recruited mast cells in the tumor microenvironment enhance bladder cancer metastasis via modulation of ERβ/CCL2/CCR2 EMT/MMP9 signals

(2015) Qun Rao et al.   Oncotarget

Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

(2015) Bin Shang et al.   Scientific Reports

Immune biomarkers associated with clinical benefit from atezolizumab (MPDL3280a; anti-PD-L1) in advanced urothelial bladder cancer (UBC)

(2015) Thomas Powles et al.   Journal for ImmunoTherapy of Cancer

790 Infiltration of CD3+ and CD68+ cells in bladder cancer is subtype specific and affects outcome of patients with muscle-invasive tumors

(2014) G. Sjödahl et al.   EUROPEAN UROLOGY SUPPLEMENTS

Tumor-Associated Neutrophils as a New Prognostic Factor in Cancer: A Systematic Review and Meta-Analysis

(2014) Meixiao Shen et al.   PLoS One

Myeloid cell biology and inhibition of anti-tumor immune responses by MPDL3280A in urothelial bladder cancer

(2014) Yuanyuan Xiao et al.   Journal for ImmunoTherapy of Cancer

Clinical significance of macrophage heterogeneity in human malignant tumors

(2013) Yoshihiro Komohara et al.   CANCER SCIENCE

Changes in the immune cell population and cell proliferation in peripheral blood after gemcitabine-based chemotherapy for pancreatic cancer

(2013) Y. Homma et al.   Clinical & Translational Oncology

Association of T-cell co-regulatory protein expression with clinical outcomes following radical cystectomy for urothelial carcinoma of the bladder

(2013) E. Xylinas et al.   EJSO

High level of mature tumor-infiltrating dendritic cells predicts progression to muscle invasion in bladder cancer

(2013) Cherifa Ayari et al.   HUMAN PATHOLOGY

Preconditioning Chemotherapy with Cisplatin Enhances the Antitumor Activity of Cytokine-Induced Killer Cells in a Murine Melanoma Model

(2012) Jing Chen et al.   CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS

Targeting Tumor-Infiltrating Macrophages Decreases Tumor-Initiating Cells, Relieves Immunosuppression, and Improves Chemotherapeutic Responses

(2012) J. B. Mitchem et al.   CANCER RESEARCH

First analysis of immune cell infiltration in stage pT1 urothelial bladder carcinoma: CD3 positivity as a prognostic marker for cancer-specific survival

(2012) Wolfgang Otto et al.   WORLD JOURNAL OF UROLOGY

Association of mast cells with microvessel density in urothelial carcinomas of the urinary bladder

(2011) Aysegul Sari et al.   Annals of Diagnostic Pathology

FOXP3 and survival in urinary bladder cancer

(2011) Malin E. Winerdal et al.   BJU INTERNATIONAL

CD169-Positive Macrophages Dominate Antitumor Immunity by Crosspresenting Dead Cell-Associated Antigens

(2010) Kenichi Asano et al.   IMMUNITY

Bladder Tumor Infiltrating Mature Dendritic Cells and Macrophages as Predictors of Response to Bacillus Calmette-Guérin Immunotherapy

(2009) Cherifa Ayari et al.   EUROPEAN UROLOGY

Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

(2009) Hanh K. Le et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Effect of Frequently Used Chemotherapeutic Drugs on Cytotoxic Activity of Human Cytotoxic T-lymphocytes

(2009) Laszlo Markasz et al.   JOURNAL OF IMMUNOTHERAPY

T-Cell Coregulatory Molecule Expression in Urothelial Cell Carcinoma: Clinicopathologic Correlations and Association with Survival

(2008) S. A. Boorjian et al.   CLINICAL CANCER RESEARCH